Akero Therapeutics (AKRO)

• Market cap: $4.34B
• 1 day: -0.2%
• 5 days: 0.52%
• 1 month: 17.33%
• 3 months: 11.25%
• 6 months: 20.41%
• Year to date: 92.63%
• 1 year: 68.77%
• 5 years: 96.12%
• 10 years: 195.25%
• Sector: Healthcare
• Industry: Biotechnology

About: Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.

Employees: 67